Erlotinib

BNF:

8.1.5

Status:

Do Not Prescribe (DNP), Red

Decision Date:

None

Comments

DO NOT PRESCRIBE (DNP): NICE TA227: Lung cancer (non small-cell, advanced or metastatic maintenance treatment).  Erlotinib (monotherapy) not recommended after platinum chemotherapy (decision date - July 2011)

RED:^1,2,3 NICE TA258: Lung cancer (non small cell, EGFR-TK mutation positive) Erlotinib – a recommended first-line option in locally advanced or metastatic non-small-cell lung cancer (decision date - July 2012)

RED:^1,2,3 NICE TA374: for treating non small cell lung cancer that has progressed after prior chemotherapy. (Decision date -  January 2016)

NHS England drug. To be used in line with NHS England commissioning intentions

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
• 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again